

MRN: \_\_\_\_\_

DOB: \_\_\_\_\_

## STANDARD Ruxience (rituximab-pvvr) PLAN OF TREATMENT for GPA or MPA

NOTE: Patient **may be ineligible** to receive rituximab if receiving antibiotics for active infectious process, antifungal therapy, active fever and/or suspected infection, newly diagnosed cardiac arrhythmias, severe abdominal pain or vomiting, and/or surgery.

1. Patient Name: \_\_\_\_\_ Height (inches): \_\_\_\_\_ Weight (lbs): \_\_\_\_\_

2. Allergies: \_\_\_\_\_

### 3. Diagnosis:

M31.30 Granulomatosis with Polyangiitis (GPA/Wegener's Granulomatosis)  M31.7 Microscopic Polyangiitis (MPA)

Other ICD-10 Code: \_\_\_\_\_ Diagnosis description: \_\_\_\_\_

### 4. Pre-medications: Administered 30 minutes prior to infusion **as selected:**

\* Premedication of Acetaminophen PO, Diphenhydramine IVP, and Methylprednisolone IVP is suggested prior to infusion

#### Acetaminophen:

- 650 mg PO
- 500 mg PO
- 325 mg PO
- 1000 mg PO

**Diphenhydramine:**  25 mg IVP,  50 mg IVP,  25 mg PO,  50mg PO or

Alternate oral antihistamine to diphenhydramine:

- Cetirizine 10 mg  Loratadine 10 mg  Fexofenadine  60mgs or  180mgs

**Methylprednisolone:**  125 mg IVP  40 mg IVP or other \_\_\_\_\_ mg IVP

Famotidine:  20mg PO,  40mg PO,  20mg IVP,  40mg IVP

Pre-medicate with other: \_\_\_\_\_

### 5. DOSE:

Ruxience (rituximab) **375mg/m<sup>2</sup>** per 250-500ml Sodium Chloride 0.9% IV to infuse per protocol **OR**

Other Dose: \_\_\_\_\_

### 6. FREQUENCY:

Orders to be completed once weekly x 4 weeks

Special orders: \_\_\_\_\_

***If adverse drug reaction occurs, utilize the ADVERSE DRUG REACTION GUIDELINES***

7. Physician's Signature: \_\_\_\_\_ / \_\_\_\_\_ Date: \_\_\_\_\_

No Stamp Signatures

(Dispense as written)

(Substitution permitted)

Printed Physician's Name with Credentials: \_\_\_\_\_ NPI: \_\_\_\_\_

MRN: \_\_\_\_\_

DOB: \_\_\_\_\_

## Guidelines for Prescribing Ruxience (rituximab-pvvr) for GPA or MPA (Required documentation with all initial referrals)

Patient Name: \_\_\_\_\_

Referral Date: \_\_\_\_\_

\_\_\_ Include signed and completed **Plan of Treatment**.

\_\_\_ Include patient demographic information and insurance information. (Copy of insurance cards if available)

\_\_\_ **Supporting clinical MD notes to include any past tried and/or failed therapies, intolerance, outcomes or contraindications to conventional therapy. Include any lab results and/or tests to support diagnosis.**

\* Rituximab, in combination with glucocorticoids, is indicated for the treatment of adult patients with Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA).

\_\_\_ If patient is switching biological therapies, then MD must specify wash-out period prior to starting Rituxan® as specified of \_\_\_\_\_ weeks. Last known biological therapy: \_\_\_\_\_ and last date received: \_\_\_\_\_. (Include copy of last Rituxan® infusion record if available and currently on therapy)

\_\_\_ Other as requested: \_\_\_\_\_  
\_\_\_\_\_

### Pre-Screening:

\_\_\_ **Required Hepatitis screening to include: Hepatitis B Surface Antigen (HBsAg) and Total Hepatitis B Core Antibody (anti- HbC)**

\*Ruxience is contraindicated in patient with active HBV. Patients who are negative for surface antigen HBsAg (-) and positive for HB core antibody HbCAB (+) or positive for surface antigen HBsAg (+), should consult liver disease experts before starting and during treatment.

\***Other:** Glucocorticoids administered as methylprednisolone 1000 mg intravenously daily for 1 to 3 days followed by oral prednisone 1 mg/kg/day (not to exceed 80 mg/day and tapered per clinical need) are recommended to treat severe vasculitis symptoms. This regimen should begin within 14 days prior to or with the initiation of rituximab-pvvr and may continue during and after the 4-week course of rituximab-pvvr treatment. Methylprednisolone Plan of Treatment are available at [www.palmettoinfusion.com](http://www.palmettoinfusion.com) if needed.

\*\* Warnings/Precautions: • **Hepatitis B Virus Reactivation**- Screen all patients for HBV infection by measuring HBsAg and anti-HBc (antibodies) before initiating treatment with Ruxience. For patients who show evidence of prior hepatitis B infection (HBsAg positive or HBsAg negative but anti-HBc positive), consult with physicians with expertise in managing hepatitis B regarding monitoring and consideration for HBV antiviral therapy before and/or during Ruxience treatment. HBV reactivation has been reported up to 24 months following completion of Rituxan® •Glucocorticoids administered methylprednisolone IV premed or its equivalent 30 minutes prior to each infusion are recommended to reduce the incidence and severity of infusion reactions. Evaluation of immunizations should be completed prior to and live vaccines should not be given before or concurrently. **Serious Infections:** including fatal, bacterial, fungal, and new or reactivated viral infections can occur during and following the completion of Ruxience. See full prescribing information.



Checklist for referrals to AccuRX Infusion Center:

Fax referral to 1-866-990-3192

- Patient demographics – address, phone number, SS#, etc.
- Insurance Information – copy of the card(s) if possible
- Plan of Treatment/Orders
- Most recent physician office notes to include tried and failed therapies – all insurance companies that require a pre-authorization require the note. This includes Medicare/Medicaid HMOs
- Any lab results or other diagnostic procedures to support the diagnosis

AccuRx Infusion Center will complete insurance verification and submit all required clinical documentation to the patient's insurance company for eligibility. Our office will notify you if any further information is required. We will review financial responsibility with the patient and refer them to any available Co-pay assistance as required. Thank you for the referral.